Press release
Perjeta and other Promising Pipeline Drugs Augur Well for HER2 Antibodies Market
Among all the chronic diseases worldwide cancer is considered to be the most prevalent disease. Approximately 1,685,210 new cancer cases were diagnosed and about 595,690 cancer deaths in the US in year 2016. Whereas around 2,600 men and 246,660 that is about 29% women were diagnosed with breast cancer in year 2016. HER2 breast cancer is one of the aggressive type of breast cancer, caused due to over-expression of the HER2 protein. Breast cancers that overexpress the HER2 protein (known as HER2+) make up about 20% of the cases. HER2 positive breast cancer inclines to grow more rapidly than HER2 negative breast cancer. The factors such as being overweight, long term heavy smoking, use of menopausal hormone therapy, alcohol consumption, physical inactivity and many more are responsible for increasing risk of breast cancer. Increasing incidence of breast cancer is expected to lead to increase in demand for targeted therapies and boost the growth of the HER2 antibodies market during the forecast period.
Browse the Comprehensive Details for the Report of HER2 Antibodies Market: http://www.transparencymarketresearch.com/her2-antibodies-market.html
Global HER2 Antibodies Market: Research Methodology
This report analyzes the current and future prospects of the HER2 antibodies market based on type of treatment drugs and geography. The research is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of the major HER2 antibody drugs in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study of company websites, annual reports, press releases, investor presentations, analyst presentation and various international and national databases. The report provides estimated market size in terms of US$ Mn for each type of treatment drug, and geography for the period 2016 to 2025, considering the macro and micro environmental factors. The revenue generated from each drug was calculated by considering number of drugs used in the treatment and their market demand and sales as per their use, number of new drug launched, trends in industry, awareness, and adoption rate across all the geographies. The prevalence of HER2 breast cancer was also considered while estimating the market revenue.
The market report comprises an elaborated executive summary, which includes market snapshot that provides information about various segments of the market. It also provides information and data analysis of the market with respect to market segments based on type of treatment drugs and geography. The market overview section of the report analyzes market dynamics such as drivers, restraints and opportunities that influence the HER2 antibodies market in the current and future scenario. The report also provides pipeline analysis of the upcoming drugs for HER2 breast cancer.
Global HER2 Antibodies Market: Competitive Landscape
Market share analysis among the market players is analyzed to signify percentage share of the major players operating in the market. All these factors will help the market players to decide about the business strategies and plans to strengthen their positions in the global market. Based on geography, the market has been analyzed for countries of North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Request for the Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7301
The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in the HER2 antibodies market report are Genentech Inc. (F. Hoffmann-La Roche Ltd.), Novartis AG, Pfizer, Inc., Abnova Corporation, InvivoGen, Celltrion, Inc., Biocon Limited, and Bio-Techne (Novus Biologicals, LLC) and some other players who are involved in the HER2 antibodies market.
About TMR
Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Perjeta and other Promising Pipeline Drugs Augur Well for HER2 Antibodies Market here
News-ID: 683163 • Views: …
More Releases from TMR - Research Reports
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during…
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the…
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016.
The global dental membrane and bone graft substitutes market is expected to…
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period.
By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment…
More Releases for HER2
HER2 negative Breast Cancer Pipeline involves 85+ key companies continuously wor …
DelveInsight's HER2 negative Breast Cancer Pipeline Insight 2022 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the HER2 negative Breast Cancer pipeline domain.
Some of the essential takeaways from the HER2 negative Breast Cancer Pipeline report:
• DelveInsight's HER2 negative Breast Cancer Pipeline analysis depicts a robust space with…
HER2 Antibodies Market Expand with Significant CAGR During 2018-2025
Global HER2 Antibodies Market: Overview
Among all the chronic diseases worldwide cancer is considered to be the most prevalent disease. Approximately 1,685,210 new cancer cases were diagnosed and about 595,690 cancer deaths in the US in year 2016. Whereas around 2,600 men and 246,660 that is about 29% women were diagnosed with breast cancer in year 2016. HER2 breast cancer is one of the aggressive type of breast cancer, caused due…
HER2 Antibodies Market to approach US$ 21,669.1 mn by 2025
A recent market intelligence study by Transparency Market Research (TMR) suggests that the global HER2 antibodies market offers lucrative opportunities as the awareness regarding breast cancer and personalized medicines spreads. Consequently, the competitive landscape of the HER2 antibodies market is already quite intense with the presence of a large number of players, both global and regional. The report identifies Pfizer, Inc., Novartis AG, Genentech Inc. by F. Hoffmann-La Roche Ltd.,…
HER2 Antibodies Market Key Trends and Forecast Research Report 2025
As per the projections of the TMR report, the demand in the global HER2 antibodies market will multiply at an impressive CAGR of 8.6% during the forecast period of 2017 to 2025, achieving an estimated global valuation of US$21,669.1 mn by the end of 2025, substantially up from its evaluated worth of US$10,087.8 mn in 2016. In the near future, new drug development is expected to be based on adjuvant…
HER2 Antibodies Market Key Trends and Forecast Research Report 2025
As per the projections of the TMR report, the demand in the global HER2 antibodies market will multiply at an impressive CAGR of 8.6% during the forecast period of 2017 to 2025, achieving an estimated global valuation of US$21,669.1 mn by the end of 2025, substantially up from its evaluated worth of US$10,087.8 mn in 2016. In the near future, new drug development is expected to be based on adjuvant…
Her2 Antibodies Market: Industry Overview and Key Factors
Global Her2 Antibodies Market: Overview
Human epidermal growth factor receptor 2 (Her2) refers to an oncogene whose over-expression or amplification is commonly associated with the development of an aggressive type of breast cancer. Patients having the over-expression of Her2 receptors are diagnosed with the help of tests such as Fluorescent In-Situ Hybridization (FISH) and Immunohistochemistry (IHC).
The American Cancer Society states that around 15-30% of breast cancer cases over-express the Her2…
